Profilin-1 contributes to cardiac injury induced by advanced glycation end-products in rats

DAFENG YANG1*, WEIWEI LIU2*, LIPING MA3, YA WANG1, JING MA1, MINNA JIANG1, XU DENG4, FANG HUANG2, TIANLUN YANG1 and MEIFANG CHEN5

1Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008; 2Department of Cardiology, The First Hospital of Changsha, Changsha, Hunan 410005; 3Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014; 4Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410006; 5Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received September 24, 2016; Accepted July 20, 2017

DOI: 10.3892/mmr.2017.7446

Abstract. Cardiac injury, including hypertrophy and fibrosis, induced by advanced glycation end products (AGEs) has an important function in the onset and development of diabetic cardiomyopathy. Profilin-1, a ubiquitously expressed and multifunctional actin-binding protein, has been reported to be an important mediator in cardiac hypertrophy and fibrosis. However, whether profilin-1 is involved in AGE-induced cardiac hypertrophy and fibrosis remains to be determined. Therefore, the present study aimed to investigate the function of profilin-1 in cardiac injury induced by AGEs. The model of cardiac injury was established by chronic tail vein injection of AGEs (50 mg/kg/day for 8 weeks) in Sprague-Dawley rats. Rats were randomly assigned to control, AGEs, AGEs + profilin-1 shRNA adenovirus vectors (AGEs + S) or AGEs + control adenovirus vectors (AGEs + V) groups. Profilin-1 shRNA adenovirus vectors were injected via the tail vein to knockdown profilin-1 expression at a dose of 3x10^9 plaque forming units every 4 weeks. Echocardiography was performed to measure cardiac contractile function. Cardiac tissues were stained with Masson's trichrome stain to evaluate ventricular remodeling. The serum levels of procollagen type III N-terminal peptide were detected by ELISA. The expression of profilin-1, receptor for AGEs (RAGE), Rho, p65, atrial natriuretic peptide, β-myosin heavy chain, matrix metalloproteinase (MMP)-2 and MMP-9 were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and/or western blot analysis and immunohistochemistry staining. The results demonstrated that chronic injection of exogenous AGEs led to cardiac dysfunction, hypertrophy and fibrosis, as determined by echocardiography, Masson trichrome staining and the expression of associated genes. The expression of profilin-1 was markedly increased in heart tissue at the mRNA and protein level following AGE administration, as determined by RT-qPCR and western blotting, which was further confirmed by immunohistochemistry staining. Furthermore, the expression of RAGE, Rho and p65 was also increased at the protein level. Notably, knockdown of profilin-1 expression ameliorated AGE-induced cardiac injury and reduced the expression of RAGE, Rho and p65. These results indicate an important role for profilin-1 in AGE-induced cardiac injury, which may provide a novel therapeutic target for patients with diabetic heart failure.

Introduction

Diabetic cardiomyopathy (DCM), characterized by the presence of functional and structural abnormalities and not coronary heart disease, hypertension or other comorbidities, is the major cause of disability and mortality in patients with diabetes (1). This indicates that DCM may be a result of direct myocardial insult, distinguishing it from structural heart disease due to vascular complications. Identifying the mechanisms involved in DCM onset and progression is important for the development of therapeutic strategies to protect against diabetic heart failure. However, the pathogenesis of DCM remains to be fully elucidated. Increasing evidence has demonstrated that advanced glycation end products (AGEs), which are generated at an increased rate under chronic long-term hyperglycemia conditions, are a major contributor in the development and progression of DCM (2-8). Clinical studies have reported that, in diabetic tissues, AGEs accumulate to levels that are 14-fold higher compared with normal...
tissues, while serum levels of AGEs are associated with the degree of left ventricular function and myocardial blood flow reserve (2-4). AGEs increase the production of intracellular reactive oxygen species (ROS) via the receptor for AGEs (RAGE), which subsequently activates associated signaling cascades that promote cardiomyocyte hypertrophy (5), apoptosis (6) and myocardial fibrosis, ultimately resulting in diastolic and systolic dysfunction (7,8). However, the underlying mechanisms responsible for myocardial injury triggered by AGEs remain to be fully elucidated.

It is established that profilin-1 is an evolutionarily conserved actin-binding protein that has an important function in the regulation of cytoskeleton dynamics by promoting actin polymerization (9). Profilin-1 also binds to poly-phosphoinositide-based lipids and various proteins with poly-L-proline motifs, and serves an important role in the regulation of membrane trafficking, the small-GTPase signaling pathway, receptor activity and potentially transcriptional activity, which indicates that profilin-1 may be a central hub that controls molecular interactions (10,11). An increasing amount of evidence has demonstrated that upregulated expression of profilin-1 is associated with endothelial dysfunction, vascular inflammation and remodeling under pathological stimulations, including AGEs (12), oxidized low-density lipoprotein (13) and angiotensin II (14,15), and is not associated with high glucose (13). Furthermore, profilin-1 may also be secreted into the extracellular space, where it functions as an extracellular ligand leading to atherogenic effects and activates various signaling pathways, including the phosphatidylinositol 3-kinase/Akt and extracellular signal-regulated kinase 1/2 pathways (16). In addition, it has been reported that profilin-1 is highly expressed in heart (17), and overexpression of profilin-1 promoted cardiac hypertrophy and contractile dysfunction in profilin-1 transgenic mice (18,19), while knockdown of profilin-1 expression in spontaneous hypertensive rats attenuated cardiac hypertrophy and fibrosis (18). A number of additional studies have indicated that the abnormality of the cytoskeleton is an ultra-early change during left ventricular hypertrophy and fibrosis, and subsequent heart failure (20,21). However, whether profilin-1 contributes to AGE-induced cardiac injury, and the underlying mechanism, remains unclear.

Due to the critical role of profilin-1 in actin dynamics, cytoskeletal reorganization and pathological vascular and cardiac hypertrophy, we hypothesize that profilin-1 may be involved in cardiac injury induced by AGEs, and that attenuated expression of profilin-1 may ameliorate AGE-induced adverse effects in the heart.

Materials and methods

Chemicals and reagents. Bovine serum albumin (BSA), D-glucose and rabbit anti-GAPDH antibody were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Rabbit anti-profilin-1 and anti-Rho antibodies were purchased from Abcam (Shanghai, China), mouse anti-RAGE antibody was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and rabbit anti-p65 antibody was obtained from Bioworld Technology, Inc. (St. Louis Park, MN, USA). Blood glucose and total cholesterol (TC) detection kits were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The procollagen type III N-terminal peptide (PIIINP) ELISA kit was purchased from Usn Life Sciences, Inc. (Wuhan, China). TRIzol reagent was purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The reverse transcription kit was obtained from Thermo Fisher Scientific, Inc. The QuantiFast SYBR Green PCR kit was from Qiagen GmbH (Hilden, Germany). The profilin-1 short hairpin RNA (shRNA) adenovirus vectors and blank control adenovirus vectors were designed and synthesized by Hanbio Biotechnology Co., Ltd. (Shanghai, China).

Preparation of AGES. AGES were prepared according to the protocol described by Wu et al (22). Briefly, BSA (10 mg/ml) was incubated in 0.2 M PBS with D-glucose (90 g/l) containing 100 U/ml penicillin and 100 µg/ml streptomycin in the dark at 37°C for 12 weeks. After 12 weeks incubation, the preparations were dialyzed three times for 18 h at 4°C against PBS (pH 7.4) each time to remove free glucose, and were subsequently separated into aliquots and stored at -20°C prior to use.

Animal protocol. Male (n=30; weight, 150±10 g; age, 1 month) Sprague-Dawley rats were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The rats were raised at an ambient temperature of 24°C with 12-h light/dark cycle and 50±5% humidity, and free access to a standard chow diet and water. Rats were randomly divided into the following four groups (n=6 each): Control, rats were treated with vehicle saline; AGES, rats were treated with AGES; AGES + S, rats were treated with AGES and profilin-1 shRNA adenovirus vectors; and AGES + V, rats were treated with AGES and blank control adenovirus vectors. For transfection efficiency detection, the remaining 6 rats were randomly divided into two groups (n=3 each) for 4 weeks treatment: Ad-vector group, rats were treated with blank control adenovirus vector; Ad-profilin-1 shRNA group, rats were treated with adenovirus vector containing profilin-1 shRNA. AGES (50 mg/kg/day) was administered by tail vein injection for 8 weeks, with the same volume of saline injected as a control. Ad-profilin-1 shRNA or blank control vector was injected twice by tail vein at a dose of 3x10⁶ plaque forming units with an interval of every 4 weeks, beginning with the initial AGES injection. The experimental procedures and protocols performed in the present study were approved by the Medicine Animal Welfare Committee of Xiangya Hospital, Central South University (Changsha, China), conforming with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication 85-23, revised 1996) (23).

Echocardiography. The cardiac contractile function in vivo was determined after 8 weeks of daily administration of AGES (50 mg/kg/day) using a BL-420E Data Acquisition and Analysis system (Chengdu TME Technology Co., Ltd., Chengdu, China). Following anesthesia with pentobarbital sodium (60 mg/kg; intraperitoneal), all rats were examined and, using the left ventricular long axis view, the following parameters were measured: Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS).
samples were collected and centrifuged for 10 min at 4°C and 3,000 g. Supernatants were stored at -80°C until the analysis of biochemistry parameters. The whole heart was harvested immediately following blood sample selection, the atrium and right ventricle were removed, and left ventricle samples were divided into the following three groups: One group was fixed with 4% paraformaldehyde at room temperature for 1 week and embedded in paraffin. Paraffin sections were used for Masson's trichrome staining and immunohistochemistry; the second group was homogenized by TRIzol reagent for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis; the final group was homogenized in radioimmunoprecipitation assay lysis buffer (P0013B; Beyotime Institute of Biotechnology, Beijing, China) at a 1:1,000 dilution at 37°C for 20 min. Following washing in PBS, sections were developed using 3,3'-diaminobenzidine tetrahydrochloride obtained from Zhongsha Golden Bridge Biotechnology Co. (cat. no. ZLI-9018) and counterstained with 50% hematoxylin for 1 week and embedded in paraffin. Paraffin sections were cut from the left ventricle at a thickness of 4 µm and were stained using a Masson's trichrome stain kit (BSBA-4079A; Zhongshan Golden Bridge Biotechnology Co., Beijing, China) for western blot analysis.

Measurement of metabolic parameters and PIIINP. Metabolic parameters, including blood glucose and TC, were detected using relevant kits. The serum levels of PIIINP were detected using an ELISA kit (cat. no. SEA573Ra), according to the manufacturer's instructions.

Protein preparation and western blotting. Total protein from left ventricle tissue samples was extracted, as described above for the preparation of serum and tissue samples, and measured using a BCA protein assay kit. Following heating at 95°C for 5 min, 20 µg/sample lysates were separated by 10 or 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% fat-free milk in TBST buffer (0.1% Tween-20 in TBS) for 90 min at room temperature, and subsequently incubated with primary antibodies against profilin-1 (cat. no. ab124904, 1:1,500 dilution), p65 (cat. no. BS1253, 1:1,000 dilution), RAGE (cat. no. sc-365154, 1:600 dilution), Rho (cat. no. ab40673, 1:1,000 dilution) and GAPDH (cat. no. G9545, 1:5,000 dilution) at 4°C overnight. Following primary antibody incubation, membranes were subsequently washed and incubated with horseradish peroxidase-conjugated goat anti-mouse (cat. no. CW0102, 1:5,000 dilution; CW Biotech, Co., Ltd., Beijing, China) or anti-rabbit IgG (cat. no. CW0103, 1:5,000 dilution; CW Biotech) secondary antibodies for 1 h at room temperature. Potent ECL kit (cat. no. 70-P1425; MultiSciences Biotech Co., Ltd., Hangzhou, China) was used to visualize proteins. The signal was detected and ratios of the target protein against the GAPDH control were calculated using the Image Lab software (version 5.2.1; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

RNA isolation and RT-qPCR. Total RNA was extracted from left ventricle tissue samples using TRIzol reagent, according to the manufacturer's instructions. The concentration and purity of isolated RNA was subsequently detected. cDNA was generated from 1 µg total RNA using a high-capacity cDNA reverse transcription kit (4368814; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Reverse transcription was performed as follows: 25°C for 10 min, 37°C for 2 h, 85°C for 5 min and stored at 4°C. GAPDH primers were purchased from Sangon Biotech Co., Ltd. (Shanghai, China) and all other primers were synthesized and purified by Sangon Biotech Co., Ltd., as listed in Table I. cDNA was quantified using a QuantiFast SYBR Green PCR kit and qPCR was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). Briefly, the amplification was performed with an initial step at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 60°C for 30 sec and extension at 60°C for 30 sec for each target gene. All amplification reactions for each sample were performed in triplicate and the results were expressed as the ratio of target genes to GAPDH mRNA using the 2-ΔΔCq method (24).

Histology and Immunohistochemistry analysis. Paraformaldehyde-fixed paraffin sections were cut from the left ventricle at a thickness of 4 µm and were stained using a Masson's trichrome stain kit (BSBA-4079A; Zhongshan Golden Bridge Biotechnology Co., Beijing, China), according to the manufacturer's instructions, to evaluate ventricular remodeling. Immunohistochemistry was performed as described previously (14). Briefly, left ventricle sections, at a thickness of 4 µm, were incubated overnight at 4°C with the primary antibody against profilin-1 (1:200 dilution), and subsequently incubated with a biotin conjugated goat anti-rabbit immunoglobulin-G secondary antibody (cat. no. ZB-2010; Zhongshan Golden Bridge Biotechnology Co., Beijing, China) at a 1:1,000 dilution at 37°C for 20 min. Following washing in PBS, sections were developed using 3,3'-diaminobenzidine tetrahydrochloride obtained from Zhongsha Golden Bridge Biotechnology Co. (cat. no. ZLI-9018) and counterstained with 50% hematoxylin for
Subsequently, sections were mounted with neutral balsam. Masson’s trichrome stain and immunohistochemistry pictures were visualized under a light microscope (magnification, x200; Nikon Corporation, Tokyo, Japan).

Statistical analysis. Data are presented as the mean ± standard deviation, n=6 per group. \( P<0.01 \) vs. control; \( P<0.05 \) vs. AGEs-only group. shRNA, short hairpin RNA; AGEs, advanced glycation end products; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; control, rats treated with vehicle saline; AGEs, rats treated with AGEs; AGEs + S, rats treated with AGEs + profilin-1 shRNA adenovirus; AGEs + V, rats treated with AGEs + control adenovirus vectors.

Results

Characteristics of the exogenous AGE infusion rat model. As presented in Table II, no significant differences were observed in the body weight, blood glucose and TC of different groups of rats following 8 weeks of treatment.

Chronic injection of AGEs causes cardiac contractile dysfunction, hypertrophy and fibrosis, and increases the expression of profilin-1. To determine whether chronic injection of AGEs has an effect on cardiac injury, the present study focused on the primary characteristics of DCM, including cardiac function, fibrosis and hypertrophy. Compared with the control group, echocardiography demonstrated that left ventricle systolic function, including LVEF and LVFS, was significantly decreased in the AGEs group (Fig. 1). In addition, the AGEs group developed cardiac fibrosis, as evidenced by markedly increased collagen deposition in the heart tissue sections, particularly around vessels, indicated by blue color in Masson’s trichrome staining (Fig. 2A). Furthermore, PIIINP expression in the serum, and MMP-2 and -9 mRNA expression in left ventricle tissues, was significantly increased in the AGEs.
group compared with the control (Fig. 2B-D). As demonstrated in Fig. 2E and F, AGEs significantly increased the expression of atrial natriuretic peptide (ANP) and β-myosin heavy chain (β-MHC) compared with the control, which indicates cardiac hypertrophy. As expected, chronic delivery of AGEs significantly increased the expression of profilin-1 compared with the control group, as determined by immunohistochemistry, western blot analysis and RT-qPCR (Fig. 3). No marked differences were observed between AGEs and AGEs + V groups (Figs. 1-3).

**Downregulation of profilin-1 expression attenuates AGE-induced cardiac dysfunction, hypertrophy and fibrosis.** To investigate the role of profilin-1 in AGE-induced cardiac dysfunction, hypertrophy and fibrosis, the present study knocked down profilin-1 expression by intravenous delivery of adenovirus expressing profilin-1 shRNA. On day 6 after the second injection of adenovirus, 50 and 40% decreases in profilin-1 expression at protein and mRNA levels were observed, respectively (Fig. 4A and B). Knockdown of profilin-1 expression improved cardiac systolic function (Fig. 1) and reduced cardiac fibrosis, as indicated by reduced collagen deposition (Fig. 2A) and reduced PIIINP, MMP-2 and MMP-9 expression (Fig. 2B-D), compared with the AGEs-only group. In addition, silencing profilin-1 expression significantly inhibited AGE-induced cardiac hypertrophy, as indicated by reduced ANP and β-MHC expression (Fig. 2E and F) compared with the AGEs-only group.

**Nuclear factor (NF)-κB and Rho signaling pathways are involved in AGE-induced cardiac injury.** Increasing evidence has indicated that AGEs activate various signaling pathways, including NF-κB and Rho/Rho-associated protein kinase (ROCK), and induces the expression of genes associated with diabetic complications by binding to RAGE (2,25,26). Due to the important role of the NF-κB signaling pathway in regulating oxidative stress, fibrosis, hypertrophy and apoptosis, and as the Rho/ROCK pathway in the actin cytoskeleton are reported to be involved DCM, p65 and Rho were selected for further investigation in the present study. Following chronic treatment with AGEs for 8 weeks, a significant increase in the expression of RAGE, p65 and Rho at the protein level was observed in left ventricle heart tissues, compared with the control group (Fig. 5). Notably, blockade of profilin-1 significantly reduced the expression of RAGE, p65 and Rho compared with the AGEs-only group (Fig. 5).
The primary findings of the present study were as follows: Chronic injection of AGEs markedly upregulated the expression of profilin-1 in vivo, which was associated with abnormal cardiac structure and function, potentially via the activation of NF-κB and Rho signaling pathways; and knocking down the expression of profilin-1 attenuated AGE-induced myocardial injury, including cardiac dysfunction, hypertrophy and fibrosis. These results indicate that profilin-1 may represent a crucial mediator in AGE-induced cardiac injury, which may be developed as a potential therapeutic target for patients with diabetes to protect against heart failure.

Cardiac hypertrophy and fibrosis are the major features of DCM, and result in ventricular dysfunction and heart failure (27,28). Evidence has indicated that increased and accelerated formation of AGEs has emerged as an important contributor to the onset and development of cardiac hypertrophy and fibrosis (2). Thus, identifying the mechanisms mediated by AGEs is essential for the development of novel therapeutic targets for the treatment of DCM. It was previously reported that intraperitoneal or tail vein injection of AGEs caused vascular impairment and remodeling (29,30), and ~70% of the injected 125I-AGE irreversibly bound to heart muscle tissues (30). Therefore, we hypothesized that increasing the circulating concentration of AGEs by tail vein injection may mimic myocardial injury in vivo. The results of the present study demonstrated that chronic injection of exogenous AGEs for 8 weeks markedly decreased cardiac contractile function, and induced cardiac hypotrophy and fibrosis (Figs. 1 and 2). However, no alterations in the circulating levels of glucose and lipids were observed (Table II), which indicates that AGEs
may have an independent effect on myocardium injury, in the absence of hyperglycemia and hyperlipidemia.

It is established that profilin-1 is a highly conserved actin binding protein that has a prominent role in various cellular processes (10). Increasing evidence indicates that, in addition to regulating actin polymerization, profilin-1 is an important molecule associated with pathological hypertrophy and fibrosis. It was previously reported that profilin-1 was upregulated 2-3-fold in hypertrophic vascular tissues and ventricular cardiomyocytes (17,18), and overexpression of profilin-1 directly caused vascular and cardiac hypertrophy and fibrosis by activating mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2 signaling pathways (17). By contrast, suppression of profilin-1 expression conferred protection against hypertrophic insult. Notably, profilin-1 overexpression-associatated ventricular hypertrophy is not only observed in the ultra-early stage (21), but also at later stages (19), which indicates that profilin-1 may function as an important regulator throughout the progression of the pathological cardiac hypertrophy. In the present study, the results demonstrated that chronic injection of AGEs significantly upregulated the mRNA and protein expression of profilin-1 in the heart, which was accompanied by cardiac hypertrophy and impaired heart function. In addition, AGE-induced cardiac fibrosis was particularly prominent in the area surrounding vessels, which is a feature of both human patients and animal models of DCM (27). However, silencing profilin-1 expression markedly attenuated the observed AGE-induced cardiac injury.

Previous studies have provided evidence that demonstrates that the activation of NF-κB and Rho/ROCK signaling pathways in the heart contributes to the development of DCM, and targeting NF-κB and Rho/ROCK signaling may improve diabetic cardiac function in patients with diabetes (31-35). The results of the present study demonstrated that chronic intravenous delivery of exogenous AGEs increased the protein expression of p65 and Rho in heart tissue, and increased protein expression of RAGE was also observed, compared with the control group. Our previous study indicated that profilin-1 may function as a common cellular molecule, and may be downstream of protein kinase C or NF-κB signaling pathways mediated by AGEs in endothelial cells (12). Therefore, we hypothesized that AGEs may activate NF-κB and Rho signaling pathways via RAGE, which results in increased profilin-1 expression. Notably, in the present study, inhibition of profilin-1 expression decreased the protein expression of p65 and Rho, and ameliorated cardiac injury, which indicates a potential positive feedback loop between profilin-1 and p65, and profilin-1 and Rho. Previous studies have demonstrated that in diabetic cardiomyocytes, actin polymerization is significantly increased (32), and the actin cytoskeleton has an important role in sustaining ROS production (31). Therefore, it may be inferred that increased profilin-1 expression induced by AGEs may cause accumulated actin polymerization and, in turn, excess ROS production, which subsequently activates NF-κB and Rho to form a positive loop.

In conclusion, the present study demonstrates that chronic delivery of AGEs promoted cardiac fibrosis and hypertrophy, impaired systolic function and upregulated profilin-1 expression, which may occur via NF-κB or Rho signaling pathways. Reducing profilin-1 expression may aid the prevention of heart injuries in patients with diabetes. Therefore, targeting
ACE2 deficiency + Advanced glycation end-products induce inflammation and peroxynitrite production. PLoS One 5: e36308, 2010.

Kooij V, Viswanathan MC, Lee DJ, Rainer PP, Schmidt W, Kronert WA, Harding SE, Kass DA, Bernstein SI, Van Eyk JE and Cammarato A: Profilin modulates sarcocomic organization and mediates cardiacmyocyte hypertrophy. Cardiovasc Res 110: 738-748, 2016.

Zhao SH, Qiu J, Wang Y, Ji X, Liu XJ, You BA, Sheng YP, Li X and Gao HQ: Profilin-1 promotes the development of hypertension-induced cardiac hypertrophy. J Hypertens 31: 576-586, 2013.

Elnakish MT, Hassanain HH and Janssen PM: Vascular remodelling-associated increase in collagen expression is linked to cardiac hypertrophy and contractile dysfunction in profilin-1 transgenic mice. J Cardiovasc Pharmacol 60: 544-552, 2012.

Hein S, Kostin S, Heling A, Maeno Y and Schaper J: The role of the cytokines in heart failure. Cardiovasc Res 45: 273-278, 2000.

Zhao SH, Gao HQ, Ji X, Wang Y, Liu XJ, You BA, Cui XP and Qiu J: Effect of ouabain on myocardial ultrastructure and cytokines during the development of ventricular hypertrophy. Heart Vessels 28: 101-113, 2013.

Wu S, Song T, Zhou X, Liu Y, Chen G, Huang N and Liu L: Identification of Nα/H exchange 1 in advanced glycation end-products-induced proliferation of vascular smooth muscle cell. Biochem Biophys Res Commun 375: 384-389, 2008.

National Institutes of Health Guide for the Care and Use of Laboratory Animals. National Academies Press 85-23 revised, Washington, DC, 1996. https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf.

Bopo W: The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 14: 724-730, 2004.

Walter W: The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 14: 724-730, 2004.

Jocksch BM, Murk K and Rothgekel M: The profile of profilins. Rev Physiol Biochem Pharmacol 159: 131-149, 2007.

Li Z, Zhang Q, Yang T, Xie X and Chen M: The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc Diabetol 12: 14, 2013.

Romeo G, Frangioni JV and Kazlauskas A: Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunction. FASEB J 18: 725-727, 2004.

Cheng JF, Ni GH, Chen MF, Li YJ, Wang YJ, Wang CL, Yuan Q, Shi RZ, Huang XJ and Yang TL: Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul Pharmacol 55: 34-41, 2011.

Jin HY, Song B, Qudit GY, Davidge ST, Yu HM, Jiang YY, Gao PJ, Zhu DL, Ning G, Kassiri Z, et al: ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 7: e38502, 2012.

References
1. Miki T, Yuda S, Kouzu H and Miura T: Diabetic cardiomyopathy: Pathophysiology and clinical features. Heart Fail Rev 18: 149-166, 2013.
2. Bodiga VL, Eda SR and Bodiga S: Advanced glycation end products: Role in pathology of diabetic cardiomyopathy. Heart Fail Rev 19: 49-63, 2014.
3. Sveen KA, Nerrudm T, Hasskén FF, Brekke M, Torjesen PA, Strauch CM, Sell DR, Monnier VM, Dahl-Jørgensen K and Steine K: Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: Associations with protein glycation. Diab Vasc Dis Res 11: 84-91, 2014.
4. Cooper ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17: 315-385, 2004.
5. Ko SY, Lin HH, Shieh TM, Ko HA, Chen HI, Chi TC, Chang SS and Hsu YC: Cell hypertrophy and MEK/ERK phosphorylation are regulated by gyceraldehyde-dehydrated AGEs in cardiomyocyte H9c2 cells. Cell Biochem Biophys 66: 537-544, 2013.
6. Li SY, Sigmon VK, Babcock SA and Ren J: Advanced glycation end product-induced ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci 80: 1051-1056, 2007.
7. Guo R, Liu W, Liu B, Zhang BL and Liu X: SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: An insight into endoplasmic reticulum stress response mechanism. Int J Cardiol 114: 156-45, 2015.
8. Brouwers O, de Vos-Houben JM, Niessen PM, Miyata T, van Nieuwvenhoen F, Janssen BHJ, Hageman G, Stehouwer CD, van der Schouw YT and Schaper J: Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression. Int J Mol Sci 14: 15724-15739, 2013.
9. Pernier J, Shekhar S, Jegou A, Guichard B and Carlier MF: Effect of ouabain on myocardial ultrastructure and cytokines during the development of ventricular hypertrophy. Heart Vessels 28: 101-113, 2013.
10. Gao PJ, Zhu DL, Ning G, Kassiri Z, et al: ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 7: e38502, 2012.